Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

LLM 2021 | Differentiating Waldenström’s macroglobulinemia and cold agglutinin disease

Sigbjorn Berentsen • 11 Oct 2021
LLM 2021
Cold Agglutinin Disease Lymphoma Non-Hodgkin Lymphoma Non-Malignant Waldenström’s Macroglobulinemia

Sigbjorn Berentsen, MD, PhD, Haugesund Hospital, Haugesund, Norway, discusses the differences between Waldenström’s macroglobulinemia (WM) and cold agglutinin disease (CAD). WM and CAD have similar features and were previously thought be to linked, but recent data have indicated that they are two separate diseases. Distinguishing features include the MYD88 L265P mutation, which is more prevalent in patients with CAD. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.

More from Sigbjorn Berentsen

2:54
Management of cold agglutinin disease
Sigbjorn Berentsen • 11 Oct 2021
1:33
Novel treatments for cold agglutinin disease
Sigbjorn Berentsen • 11 Oct 2021

Related Videos

2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals